Supply Chain
Assessment for CGT

Cell and gene therapies are distinctly different from traditional biopharma product and their supply chains require uniquely designed logistics solutions for optimal patient delivery and administration.

Helping you address complex supply chain challenges

 

Materials produced for autologous and allogeneic therapies must be shipped under strict temperature controls within extremely tight timelines, and with full traceability always. HiTech Health can help you address complex supply chain challenges and provide end-to-end assistance with managing all aspects to ensure the products are manufactured and supplied to patients efficiently and effectively.

HiTech Health can assist you with:

 

  • Day-to-day management of supply chain activities.
  • Coordination between CMOs, treatment centres and logistics providers.
  • Supply chain risk assessments and mitigation plans.
  • Selection of supply chain vendors.
  • Evaluation of CGT supply chain and improvements.
  • Responsible Person (RP) services for CGT.

2023 ATMP Review

The Advanced Therapeutic Medicinal Products (ATMPs) sector is evolving rapidly and new products have already demonstrated the ability to reverse or significantly impact the progression of disease. In recent years, the advent of cell and gene therapies has shown the...

Stay Up To Date

Connect with us to receive the latest HiTech Health and industry updates.